Co-Diagnostics (CODX) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $0.1 million, down from $0.5 million year-over-year, mainly due to lower product and grant revenues.

• Net loss narrowed to $7.5 million ($0.24 per share) from $9.3 million ($0.31 per share) year-over-year, driven by reduced operating expenses.

• Operating expenses decreased to $8.6 million from $10.5 million year-over-year.

• The company is advancing its CODEX/Co-Dx PCR platform, targeting clinical evaluations for TB, COVID-19, respiratory, and HPV panels in 2025.

• Cash, cash equivalents, and marketable securities totaled $21.5 million as of March 31, 2025.

Financial highlights

• Product revenue was $50,277 in Q1 2025, compared to $252,745 in Q1 2024; no grant revenue recognized in Q1 2025.

• Gross profit was $28,687 in Q1 2025, down from $233,349 in Q1 2024.

• Adjusted EBITDA loss was $7.4 million, compared to $8.4 million in Q1 2024.

• Net cash used in operating activities was $8.7 million, slightly higher than $8.5 million in Q1 2024.

• Other income, net, was $1.03 million, including interest income and realized gains.

Outlook and guidance

• Clinical trials for COVID-19, TB, HPV, and respiratory panels expected to commence in 2025.

• Regulatory submissions planned for India, South Africa, and the US, with initial commercialization targeted post-approval.

• Manufacturing facility build-out in India on track for completion by year-end.

• Management anticipates continued operating losses and cash use in the near term, with additional financing likely needed.

• Margins for new products expected to be similar to historical lab-based tests.